Although there is no one arguing that the stock price is not depressing, let's remember that Jason Napodano is not some analyst god from Goldman Sachs. He has been wrong - very wrong - on some of his calls.

Let's focus on the last word we got from the company earlier this month.

Quote:

---

Next Steps for Amarantus

 Uplist to NASDAQ as rapidly as possible
 Focus on Operational Excellence with therapeutic programs
to advance to key data milestones
 Complete strategic transaction with Amarantus Diagnostics

We are prepared to enter our next phase of growth!

---

I think they are working hard on the strategic transaction and they will uplist following September 4.

And the price will react accordingly.